Grundinformationen
- Standard-SMILES
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl- InChIKey
MWWSFMDVAYGXBV-RUELKSSGSA-N- Summenformel
- C27H29NO11.ClH
- Durchschnittliche Molmasse
- 580 g/mol
- Monoisotopische Masse
- 579,15073846
Überblick
Doxorubicin Hydrochloride (Adriamycin) can cause cancer according to an independent committee of scientific and health experts. It can cause developmental toxicity and male reproductive toxicity according to state or federal government labeling requirements.
Namen und Bezeichner
- Bevorzugter Name
- Doxorubicin Hydrochloride
- IUPAC
- (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
Namen und Synonyme
Doxorubicin Hydrochloride25316-40-9Doxorubicin HClADRIAMYCIN HYDROCHLORIDEAdriacinAdriamycin PFSAdriamycin RDFADRIAMYCIN, HYDROCHLORIDEAdriablastina csDTXSID3030636doxorubicin.HClDoxorubicini hydrochloridum
Weitere Namen anzeigen
hydroxydaunomycin hydrochloride82F2G7BL4EDoxorubicin citric acid saltDTXCID1010636Liposomal doxorubicin hydrochlorideDOXORUBICIN HYDROCHLORIDE LIPOSOME5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-FI 106
Datenbank-Bezeichner
- CAS
25316-40-9- PubChem CID
- 443939
- DTXSID
DTXSID3030636- ChEMBL
CHEMBL359744- ChEBI
CHEBI:31522- UNII
- 82F2G7BL4E
- EC Number
- 246-818-3
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 206 Ų
- H-Brücken-Donoren
- 7
- H-Brücken-Akzeptoren
- 12
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 40
- Formalladung
- 0
- Komplexität
- 977
Experimentelle und physikochemische Eigenschaften
SolubilitySoluble (NTP, 1992)
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Anthracyclines; Antibiotics, Antineoplastic; Topoisomerase II Inhibitors
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
Melting Point399 to 401 °F (Decomposes) (NTP, 1992)
Physical DescriptionAdriamycin hydrochloride appears as orange-red thin needles. Aqueous solutions yellow-orange at acid pHs, orange-red at neutral pHs, and violet blue over pH 9. (NTP, 1992)
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Danger
H302 (77.8%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 158 reports by companies from 22 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory Information
Hazard Traits - Carcinogenicity; Developmental Toxicity; Reproductive Toxicity
Adriamycin hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Fire HazardsThis compound is probably combustible. (NTP, 1992)
Reactive GroupAmines, Phosphines, and Pyridines
Reactivity Profile
Amines, like adriamycin hydrochloride, are weak chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.
Air and Water ReactionsWater soluble.
Hazard Classes and CategoriesAcute Tox. 4 (77.8%)
Sicherheit und Schutzausrüstung
Fire FightingFires involving this material can be controlled with a dry chemical carbon dioxide, foam or Halon extinguisher. (NTP, 1992)
First Aid
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
Personal Protective Equipment (PPE)MINIMUM PROTECTIVE CLOTHING: If Tyvek-type disposable protective clothing is not worn during handling of this chemical, wear disposable Tyvek-type sleeves taped to your gloves.
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Doxorubicin hydrochloride
vLess-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
DOXORUBICIN HYDROCHLORIDE
Anthracycline Topoisomerase Inhibitor [EPC]; Anthracyclines [CS]; Topoisomerase Inhibitors [MoA]
DOXORUBICIN HYDROCHLORIDE LIPOSOME
Topoisomerase Inhibitors [MoA]; Anthracyclines [CS]; Anthracycline Topoisomerase Inhibitor [EPC]
MeSH Pharmacological Classification
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
Zugehörige Reaktionen
54
Verknüpfte Notizen
Wird geladen…